Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 22:13:3771-3781.
doi: 10.2147/IDR.S273759. eCollection 2020.

Pseudomonas aeruginosa Type III Secretion System Virulotypes and Their Association with Clinical Features of Cystic Fibrosis Patients

Edilene do Socorro Nascimento Falcão Sarges  1   2 , Yan Corrêa Rodrigues  1 , Ismari Perini Furlaneto  3 , Marcos Vinicios Hino de Melo  1 , Giulia Leão da Cunha Brabo  4 , Kátia Cilene Machado Lopes  2 , Ana Judith Pires Garcia Quaresma  4 , Luana Nepomuceno Godim Costa Lima  1   4 , Karla Valéria Batista Lima  1   4
Affiliations

Pseudomonas aeruginosa Type III Secretion System Virulotypes and Their Association with Clinical Features of Cystic Fibrosis Patients

Edilene do Socorro Nascimento Falcão Sarges et al. Infect Drug Resist. .

Abstract

Purpose: Pseudomonas aeruginosa appears as the main pathogen in cystic fibrosis (CF) involved in recurrent pneumonia and pulmonary exacerbations. The type III secretion system (T3SS) is one of its main determinants of virulence and is associated with poor clinical progression and increased mortality. This study determined the relationship of clinical features of patients with CF and P. aeruginosa T3SS virulotypes.

Materials and methods: From January 2018 to March 2019, P. aeruginosa were isolated from sputum and/or oropharyngeal swabs. T3SS markers (exoS, exoU, exoT and exoY) were detected by PCR. Clinical severity according to Shwachman-Kulckycki score and spirometry data were associated with T3SS virulotypes.

Results: A total of 49 patients had positive cultures for P. aeruginosa. T3SS virulence-related markers were detected as follows: exoS 97.9% (n=48), exoU 63.2% (n=31), exoT 95.9% (n=47) and exoY 97.9% (n=48). The prevalence of exoS+/exoU+ virulotype was higher than previously reported in CF settings, being detected in 61.2% of the evaluated isolates, present in 70% of intermittent infections and with a significantly higher frequency in cases of exacerbations. The presence of exoU in chronic infection was not associated with poor clinical results. In chronic infections, the exoS+/exoU- virulotype prevailed (77.8%) and was associated to worse clinical results according to the Shwachman-Kulckycki score and spirometric.

Conclusion: Our findings revealed a high prevalence of the atypical exoS+/exoU+ virulotype among P. aeruginosa isolates from patients with CF, which was associated with intermittent infection and early clinical alterations, while the exoS+/exoU- virulotype was associated with chronic infection and worse clinical results. Finally, the presented data highlight the relevance of T3SS virulence markers in the clinical progression and disease severity in CF patients.

Keywords: exoS; exoT; exoU; exoY; type III secretory system; virulence genes.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Athanazio RA, da Silva Filho LVRF, Vergara AA, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219–245. - PMC - PubMed
    1. Marson FAL, Hortencio TDR, Aguiar KCA, et al. Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. BMC Pulm Med. 2015;15(3). doi:10.1186/1471-2466-15-3. - DOI - PMC - PubMed
    1. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. doi:10.1016/S0140-6736(16)00576-6 - DOI - PubMed
    1. Silva Filho LVRFD, Ferreira FDA, Reis FJC, et al. Infecção por Pseudomonas aeruginosa em pacientes com fibrose cística: evidências científicas sobre o impacto clínico, diagnóstico e tratamento. J Bras Pneumol. 2013;39(4):495–512. doi:10.1590/S1806-37132013000400015 - DOI - PMC - PubMed
    1. Crull MR, Ramos KJ, Caldwell E, Mayer-Hamblett N, Aitken ML, Goss CH. Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time. BMC Pulm Med. 2016;16(1):1–7. doi:10.1186/s12890-016-0333-y - DOI - PMC - PubMed

LinkOut - more resources